Non-Hodgkin lymphoma (NHL) is a group of hematologic malignancies that originate from lymphocytes known as B or T cells. This ...

Please provide your email address to receive an email when new articles are posted on . CHICAGO — In this video, Jeremy S. Abramson, MD, discusses 2-year results from the phase 3 STARGLO trial, which ...

Researchers found that loss of HDAC7 disrupted B-cell maturation in mouse models. Restoring HDAC7 suppressed tumor growth, ...

A research team at the University of Cologne's Center for Molecular Medicine Cologne (CMMC) has discovered that the protein ...

Has come back (relapsed) within a year of treatment or does not go away (refractory) after your first treatment Has relapsed or is refractory and you cannot receive a hematopoietic stem cell ...

Researchers found that targeting cFLIP re-sensitized lymphoma cells to death signals in preclinical mouse models of DLBCL.

Diffuse large B-cell lymphoma is a common type of non-Hodgkin’s lymphoma that also has a high rate of relapse. Common signs of a relapse include lymph node swelling, as well as the development of “B ...

Roche has demonstrated the power of combining two of oncology’s hottest modalities—bispecifics and antibody-drug conjugates (ADCs)—in a Lunsumio-Polivy regimen in large B-cell lymphoma (LBCL). The ...

Fred Locke, MD, Moffitt Cancer Center, explains why this hematologic cancer is such an attractive target for chimeric antigen receptor (CAR) T-cell therapy, specifically allogeneic, which uses healthy ...

How Can Biomarkers Help Individualize Treatment of Diffuse Large B-cell Lymphoma? Using Biomarkers to Diagnose Diffuse Large B-cell Lymphoma ...